Document Detail


Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan.
MedLine Citation:
PMID:  20490611     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
There is no previous report of fatal interstitial pneumonitis related to the administration of yttirum-90 ibritumomab tiuxetan. We report first case of fatal interstitial pneumonitis in a 35-year-old female patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan. A pathological evaluation through a surgical lung biopsy demonstrated a "interstitial pneumonitis" pattern. Although high-dose methylprednisolone was administered, she died due to acute respiratory distress syndrome, secondary to radioimmunotherapy-induced interstitial pneumonitis. In this report, we discuss the etiology, diagnosis, and management of radioimmunotherapy-induced interstitial pneumonitis.
Authors:
Moon Jin Kim; Gyeong-Won Lee; Jong Woo Seo; Hyun-Jung Kim; Sung-Nam Lim; Cheolwon Suh
Publication Detail:
Type:  Journal Article     Date:  2010-05-21
Journal Detail:
Title:  Investigational new drugs     Volume:  29     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-08-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1098-101     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inhibition of lindane-induced toxicity using alpha-lipoic acid and vitamin E in the brain of Mus mus...
Next Document:  Morphologic magnetic resonance imaging features of therapy-induced cerebral necrosis.